{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:11:13Z","timestamp":1783905073588,"version":"3.55.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,11]]},"DOI":"10.7759\/cureus.112496","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:39:10Z","timestamp":1783903150000},"source":"Crossref","is-referenced-by-count":0,"title":["Gene Therapy for Lipid Management: Dawn of a New Era"],"prefix":"10.7759","author":[{"given":"Prabhash C","family":"Manoria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/cells15020134","article-title":"Gene editing therapies targeting lipid metabolism for cardiovascular disease: tools, delivery strategies, and clinical progress","volume":"15","author":"Ren Z","year":"2026","unstructured":"Ren Z, Zhou J, Yang D, Guo Y, Zhang J, Xu J, Chen YE. Gene editing therapies targeting lipid metabolism for cardiovascular disease: tools, delivery strategies, and clinical progress. Cells. 2026, 15:134. 10.3390\/cells15020134","journal-title":"Cells"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00119-5","article-title":"Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17)","volume":"11","author":"Anjana RM","year":"2023","unstructured":"Anjana RM, Unnikrishnan R, Deepa M, et al.. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023, 11:474-89. 10.1016\/S2213-8587(23)00119-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s41043-025-01054-3","article-title":"Global prevalence of dyslipidemias in the general adult population: a systematic review and meta-analysis","volume":"44","author":"Ballena-Caicedo J","year":"2025","unstructured":"Ballena-Caicedo J, Zuzunaga-Montoya FE, Loayza-Castro JA, V\u00e1squez-Romero LE, Tapia-Limonchi R, De Carrillo CI, Vera-Ponce VJ. Global prevalence of dyslipidemias in the general adult population: a systematic review and meta-analysis. J Health Popul Nutr. 2025, 44:308. 10.1186\/s41043-025-01054-3","journal-title":"J Health Popul Nutr"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-023-00860-8","article-title":"Novel and future lipid-modulating therapies for the prevention of cardiovascular disease","volume":"20","author":"Brandts J","year":"2023","unstructured":"Brandts J, Ray KK. Novel and future lipid-modulating therapies for the prevention of cardiovascular disease. Nat Rev Cardiol. 2023, 20:600-16. 10.1038\/s41569-023-00860-8","journal-title":"Nat Rev Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1757070","article-title":"Gene-based therapy in lipid management: the winding road from promise to practice","volume":"29","author":"Tromp TR","year":"2020","unstructured":"Tromp TR, Stroes ES, Hovingh GK. Gene-based therapy in lipid management: the winding road from promise to practice. Expert Opin Investig Drugs. 2020, 29:483-93. 10.1080\/13543784.2020.1757070","journal-title":"Expert Opin Investig Drugs"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110641","article-title":"Recent progress in gene therapy for familial hypercholesterolemia treatment","volume":"27","author":"Luo Y","year":"2024","unstructured":"Luo Y, Hou Y, Zhao W, Yang B. Recent progress in gene therapy for familial hypercholesterolemia treatment. iScience. 2024, 27:110641. 10.1016\/j.isci.2024.110641","journal-title":"iScience"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby J","year":"2014","unstructured":"Crosby J, Peloso GM, Auer PL, et al.. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014, 371:22-31. 10.1056\/NEJMoa1307095","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2217\/clp.10.73","article-title":"Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies","volume":"5","author":"Kassim SH","year":"2010","unstructured":"Kassim SH, Wilson JM, Rader DJ. Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies. Clin Lipidol. 2010, 5:793-809. 10.2217\/clp.10.73","journal-title":"Clin Lipidol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach F","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al.. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020, 41:111-88. 10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference BA","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al.. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017, 38:2459-72. 10.1093\/eurheartj\/ehx144","journal-title":"Eur Heart J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray KK","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, et al.. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021, 28:1279-89. 10.1093\/eurjpc\/zwaa047","journal-title":"Eur J Prev Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01122-3","article-title":"Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)","volume":"398","year":"2021","unstructured":"Global perspective of familial hypercholesterolaemia. a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet. 2021, 398:1713-25. 10.1016\/S0140-6736(21)01122-3","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf411","article-title":"Gene therapy and genome editing for lipoprotein disorders","volume":"46","author":"Gurevitz C","year":"2025","unstructured":"Gurevitz C, Bajaj A, Khera AV, Do R, Schunkert H, Musunuru K, Rosenson RS. Gene therapy and genome editing for lipoprotein disorders. Eur Heart J. 2025, 46:3420-33. 10.1093\/eurheartj\/ehaf411","journal-title":"Eur Heart J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwab154","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"29","author":"Visseren FL","year":"2022","unstructured":"Visseren FL, Mach F, Smulders YM, et al.. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol. 2022, 29:5-115. 10.1093\/eurjpc\/zwab154","journal-title":"Eur J Prev Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2021.10.024","article-title":"LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC\/EAS lipid guidelines: implications for newer lipid-lowering treatments","volume":"345","author":"Rizos CV","year":"2021","unstructured":"Rizos CV, Skoumas I, Rallidis L, et al.. LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC\/EAS lipid guidelines: implications for newer lipid-lowering treatments. Int J Cardiol. 2021, 345:119-24. 10.1016\/j.ijcard.2021.10.024","journal-title":"Int J Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2020.07.018","article-title":"Very high-risk familial hypercholesterolaemia patients in real life: the remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors","volume":"309","author":"Rallidis LS","year":"2020","unstructured":"Rallidis LS, Liberopoulos EN, Vlachopoulos C, et al.. Very high-risk familial hypercholesterolaemia patients in real life: the remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors. Atherosclerosis. 2020, 309:67-9. 10.1016\/j.atherosclerosis.2020.07.018","journal-title":"Atherosclerosis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/20523211.2024.2421261","article-title":"Lipid-lowering agent preferences among patients with hypercholesterolemia: a focus group study","volume":"17","author":"Yiu HH","year":"2024","unstructured":"Yiu HH, Deng K, Fung LW, et al.. Lipid-lowering agent preferences among patients with hypercholesterolemia: a focus group study. J Pharm Policy Pract. 2024, 17:2421261. 10.1080\/20523211.2024.2421261","journal-title":"J Pharm Policy Pract"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-customized oligonucleotide therapy for a rare genetic disease","volume":"381","author":"Kim J","year":"2019","unstructured":"Kim J, Hu C, Moufawad El Achkar C, et al.. Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Med. 2019, 381:1644-52. 10.1056\/NEJMoa1813279","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference BA","year":"2019","unstructured":"Ference BA, Kastelein JJ, Ray KK, et al.. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019, 321:364-73. 10.1001\/jama.2018.20045","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-019-0791-9","article-title":"Emerging evidence that ApoC-III inhibitors provide novel options to reduce the residual CVD","volume":"21","author":"Taskinen MR","year":"2019","unstructured":"Taskinen MR, Packard CJ, Bor\u00e9n J. Emerging evidence that ApoC-III inhibitors provide novel options to reduce the residual CVD. Curr Atheroscler Rep. 2019, 21:27. 10.1007\/s11883-019-0791-9","journal-title":"Curr Atheroscler Rep"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett CF","year":"2010","unstructured":"Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010, 50:259-93. 10.1146\/annurev.pharmtox.010909.105654","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair JK","year":"2014","unstructured":"Nair JK, Willoughby JL, Chan A, et al.. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014, 136:16958-61. 10.1021\/ja505986a","journal-title":"J Am Chem Soc"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali P","year":"2013","unstructured":"Mali P, Yang L, Esvelt KM, et al.. RNA-guided human genome engineering via Cas9. Science. 2013, 339:823-6. 10.1126\/science.1232033","journal-title":"Science"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-025-00575-0","article-title":"Therapeutic precision gene editing of cholesterol pathways as a gene therapy strategy for cardiovascular disease","volume":"33","author":"Erbasan E","year":"2026","unstructured":"Erbasan E, Aliciaslan M, Erendor F, Sanlioglu AD, Sanlioglu S. Therapeutic precision gene editing of cholesterol pathways as a gene therapy strategy for cardiovascular disease. Gene Ther. 2026, 33:218-37. 10.1038\/s41434-025-00575-0","journal-title":"Gene Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2023.08.010","article-title":"New opportunities in the management and treatment of refractory hypercholesterolemia using in\u00a0vivo CRISPR-mediated genome\/base editing","volume":"33","author":"Srivastava RA","year":"2023","unstructured":"Srivastava RA. New opportunities in the management and treatment of refractory hypercholesterolemia using in\u00a0vivo CRISPR-mediated genome\/base editing. Nutr Metab Cardiovasc Dis. 2023, 33:2317-25. 10.1016\/j.numecd.2023.08.010","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511778","article-title":"Phase 1 trial of CRISPR-Cas9 gene editing targeting ANGPTL3","volume":"393","author":"Laffin LJ","year":"2025","unstructured":"Laffin LJ, Nicholls SJ, Scott RS, et al.. Phase 1 trial of CRISPR-Cas9 gene editing targeting ANGPTL3. N Engl J Med. 2025, 393:2119-30. 10.1056\/NEJMoa2511778","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvad095","article-title":"First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA","volume":"10","author":"Lewis BS","year":"2024","unstructured":"Lewis BS. First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA. Eur Heart J Cardiovasc Pharmacother. 2024, 10:87-8. 10.1093\/ehjcvp\/pvad095","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2025.04.095","article-title":"\u2020 VERVE-102, a clinical stage in vivo base editing medicine, leads to potent and precise inactivation of PCSK9 in preclinical studies","volume":"19","author":"Flight P","year":"2025","unstructured":"Flight P, Rohde E, Lee R, et al.. \u2020 VERVE-102, a clinical stage in vivo base editing medicine, leads to potent and precise inactivation of PCSK9 in preclinical studies. J Clin Lipidol. 2025, 19:E68. 10.1016\/j.jacl.2025.04.095","journal-title":"J Clin Lipidol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-026-02605-8","article-title":"CRISPR gene editing of angiopoietin-like 3: toward one-time precision therapy for dyslipidaemia","volume":"11","author":"Mondal A","year":"2026","unstructured":"Mondal A, Misra A. CRISPR gene editing of angiopoietin-like 3: toward one-time precision therapy for dyslipidaemia. Signal Transduct Target Ther. 2026, 11:77. 10.1038\/s41392-026-02605-8","journal-title":"Signal Transduct Target Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S521579","article-title":"Small interfering RNA (siRNA) in dyslipidemia: a systematic review on safety and efficacy of siRNA","volume":"17","author":"Alla SS","year":"2025","unstructured":"Alla SS, Shah DJ, Meyur S, et al.. Small interfering RNA (siRNA) in dyslipidemia: a systematic review on safety and efficacy of siRNA. J Exp Pharmacol. 2025, 17:249-67. 10.2147\/JEP.S521579","journal-title":"J Exp Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1736821","article-title":"Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis","volume":"17","author":"Gao Y","year":"2026","unstructured":"Gao Y, Bai Y, Mu X, Pang X. Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis. Front Pharmacol. 2026, 17:1736821. 10.3389\/fphar.2026.1736821","journal-title":"Front Pharmacol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2023.03.020","article-title":"siRNA targeting ANGPTL3 stands in the spotlight for lipid-lowering therapy","volume":"32","author":"Hu B","year":"2023","unstructured":"Hu B, Huang Y. siRNA targeting ANGPTL3 stands in the spotlight for lipid-lowering therapy. Mol Ther Nucleic Acids. 2023, 32:369-70. 10.1016\/j.omtn.2023.03.020","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.12997\/jla.2022.11.3.250","article-title":"A new modality in dyslipidemia treatment: antisense oligonucleotide therapy","volume":"11","author":"Kim K","year":"2022","unstructured":"Kim K, Choi SH. A new modality in dyslipidemia treatment: antisense oligonucleotide therapy. J Lipid Atheroscler. 2022, 11:250-61. 10.12997\/jla.2022.11.3.250","journal-title":"J Lipid Atheroscler"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s40292-024-00682-w","article-title":"Antisense oligonucleotides in dyslipidemia management: a review of clinical trials","volume":"32","author":"Ogieuhi IJ","year":"2025","unstructured":"Ogieuhi IJ, Callender K, Odukudu GO, et al.. Antisense oligonucleotides in dyslipidemia management: a review of clinical trials. High Blood Press Cardiovasc Prev. 2025, 32:33-47. 10.1007\/s40292-024-00682-w","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal FJ","year":"2010","unstructured":"Raal FJ, Santos RD, Blom DJ, et al.. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010, 375:998-1006. 10.1016\/S0140-6736(10)60284-X","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(24)03660-X","article-title":"A randomized, placebo-controlled phase 3 study of olezarsen in patients with familial chylomicronemia syndrome","volume":"83","author":"Stroes ES","year":"2024","unstructured":"Stroes ES, Alexander V, Prokopczuk E, et al.. A randomized, placebo-controlled phase 3 study of olezarsen in patients with familial chylomicronemia syndrome. J Am Coll Cardiol. 2024, 83:1670. 10.1016\/S0735-1097(24)03660-X","journal-title":"J Am Coll Cardiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2512761","article-title":"Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk","volume":"394","author":"Marston NA","year":"2026","unstructured":"Marston NA, Bergmark BA, Alexander VJ, et al.. Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk. N Engl J Med. 2026, 394:429-41. 10.1056\/NEJMoa2512761","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.25259\/IJCDW_66_2025","article-title":"Safety and efficacy of novel agents: pelacarsen, obicetrapib, and beyond","volume":"10","author":"Palimkar P","year":"2025","unstructured":"Palimkar P, Satish P, Rajendran RJ, Rath HM, Sharma R. Safety and efficacy of novel agents: pelacarsen, obicetrapib, and beyond. Indian J Cardiovasc Dis Women. 2025, 10:334-9. 10.25259\/IJCDW_66_2025","journal-title":"Indian J Cardiovasc Dis Women"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa001","article-title":"Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease","volume":"13","author":"Fernandez-Prado R","year":"2020","unstructured":"Fernandez-Prado R, Perez-Gomez MV, Ortiz A. Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease. Clin Kidney J. 2020, 13:753-7. 10.1093\/ckj\/sfaa001","journal-title":"Clin Kidney J"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehag073","article-title":"Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial","volume":"47","author":"Parhofer KG","year":"2026","unstructured":"Parhofer KG, Julius U, Herzog AL, et al.. Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial. Eur Heart J. 2026, 47:3284-94. 10.1093\/eurheartj\/ehag073","journal-title":"Eur Heart J"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S338424","article-title":"Inclisiran: a new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease","volume":"19","author":"Albosta MS","year":"2023","unstructured":"Albosta MS, Grant JK, Taub P, Blumenthal RS, Martin SS, Michos ED. Inclisiran: a new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease. Vasc Health Risk Manag. 2023, 19:421-31. 10.2147\/VHRM.S338424","journal-title":"Vasc Health Risk Manag"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-026-05515-3","article-title":"Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management","volume":"26","author":"Satyam SM","year":"2026","unstructured":"Satyam SM, El-Tanani M, Patni MA, et al.. Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management. BMC Cardiovasc Disord. 2026, 26:94. 10.1186\/s12872-026-05515-3","journal-title":"BMC Cardiovasc Disord"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2024.10.017","article-title":"Safety and efficacy of inclisiran in treating hypercholesterolemia: a systemic review and meta-analysis","volume":"35","author":"Cheng Z","year":"2025","unstructured":"Cheng Z, Gao M, Liu Y, Yan W, Zhang Z, Jiao N, Li C. Safety and efficacy of inclisiran in treating hypercholesterolemia: a systemic review and meta-analysis. Nutr Metab Cardiovasc Dis. 2025, 35:103779. 10.1016\/j.numecd.2024.10.017","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13020141","article-title":"The safety profile of inclisiran in patients with dyslipidemia: a systematic review and meta-analysis","volume":"13","author":"Maliha M","year":"2025","unstructured":"Maliha M, Satish V, Kumar SS, et al.. The safety profile of inclisiran in patients with dyslipidemia: a systematic review and meta-analysis. Healthcare (Basel). 2025, 13:141. 10.3390\/healthcare13020141","journal-title":"Healthcare (Basel)"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts GF","year":"2025","unstructured":"Watts GF, Rosenson RS, Hegele RA, et al.. Plozasiran for managing persistent chylomicronemia and pancreatitis risk. N Engl J Med. 2025, 392:127-37. 10.1056\/NEJMoa2409368","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue ML","year":"2022","unstructured":"O'Donoghue ML, Rosenson RS, Gencer B, et al.. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022, 387:1855-64. 10.1056\/NEJMoa2211023","journal-title":"N Engl J Med"},{"key":"ref47","unstructured":"ClinicalTrials.gov. A study to investigate the effect of lepodisiran on the reduction of major adverse cardiovascular events in adults with elevated lipoprotein(a) - ACCLAIM-Lp(a). (2026). Accessed. June 18, 2026: https:\/\/clinicaltrials.gov\/study\/NCT06292013."},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran-a small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial","volume":"332","author":"Nissen SE","year":"2024","unstructured":"Nissen SE, Wang Q, Nicholls SJ, et al.. Zerlasiran-a small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial. JAMA. 2024, 332:1992-2002. 10.1001\/jama.2024.21957","journal-title":"JAMA"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.24017","article-title":"Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial","volume":"333","author":"Nicholls SJ","year":"2025","unstructured":"Nicholls SJ, Ni W, Rhodes GM, et al.. Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial. JAMA. 2025, 333:222-31. 10.1001\/jama.2024.24017","journal-title":"JAMA"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.16503","article-title":"Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial","volume":"330","author":"Nicholls SJ","year":"2023","unstructured":"Nicholls SJ, Nissen SE, Fleming C, et al.. Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial. JAMA. 2023, 330:1042-53. 10.1001\/jama.2023.16503","journal-title":"JAMA"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27020921","article-title":"Angiopoietin-like protein 3 (ANGPTL3) targeting in the management of dyslipidemias","volume":"27","author":"Kosmas CE","year":"2026","unstructured":"Kosmas CE, Rallidis LS, Hoursalas I, Papakonstantinou EJ, Kostara CE. Angiopoietin-like protein 3 (ANGPTL3) targeting in the management of dyslipidemias. Int J Mol Sci. 2026, 27:921. 10.3390\/ijms27020921","journal-title":"Int J Mol Sci"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.059266","article-title":"Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70","volume":"145","author":"Bergmark BA","year":"2022","unstructured":"Bergmark BA, Marston NA, Bramson CR, et al.. Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70. Circulation. 2022, 145:1377-86. 10.1161\/CIRCULATIONAHA.122.059266","journal-title":"Circulation"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00507-0","article-title":"Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3):\u2008a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Ray KK","year":"2025","unstructured":"Ray KK, Oru E, Rosenson RS, et al.. Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3):\u2008a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2025, 405:1594-607. 10.1016\/S0140-6736(25)00507-0","journal-title":"Lancet"},{"key":"ref54","unstructured":"ClinicalTrials.gov. A phase 3 study of zodasiran in adolescent and adult subjects with homozygous familial hypercholesterolemia (YOSEMITE). (2026). Accessed. June 10, 2026: https:\/\/clinicaltrials.gov\/study\/NCT07037771."},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2023.01.010","article-title":"Gene editing for dyslipidemias: new tools to \"cut\" lipids","volume":"368","author":"Stankov S","year":"2023","unstructured":"Stankov S, Cuchel M. Gene editing for dyslipidemias: new tools to \"cut\" lipids. Atherosclerosis. 2023, 368:14-24. 10.1016\/j.atherosclerosis.2023.01.010","journal-title":"Atherosclerosis"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-024-01198-3","article-title":"Gene editing for the treatment of hypercholesterolemia","volume":"26","author":"Hoekstra M","year":"2024","unstructured":"Hoekstra M, Van Eck M. Gene editing for the treatment of hypercholesterolemia. Curr Atheroscler Rep. 2024, 26:139-46. 10.1007\/s11883-024-01198-3","journal-title":"Curr Atheroscler Rep"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001296","article-title":"Gene therapy in cardiovascular disease: recent advances and future directions in science: a science advisory from the American Heart Association","volume":"150","author":"Kim Y","year":"2024","unstructured":"Kim Y, Landstrom AP, Shah SH, Wu JC, Seidman CE. Gene therapy in cardiovascular disease: recent advances and future directions in science: a science advisory from the American Heart Association. Circulation. 2024, 150:e471-80. 10.1161\/CIR.0000000000001296","journal-title":"Circulation"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11226773","article-title":"Recent advances in gene therapy for familial hypercholesterolemia: an update review","volume":"11","author":"Fu Q","year":"2022","unstructured":"Fu Q, Hu L, Shen T, Yang R, Jiang L. Recent advances in gene therapy for familial hypercholesterolemia: an update review. J Clin Med. 2022, 11:6773. 10.3390\/jcm11226773","journal-title":"J Clin Med"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59497","article-title":"Racial and socioeconomic determinants of cardiovascular health: a comprehensive review","volume":"16","author":"Borkowski P","year":"2024","unstructured":"Borkowski P, Borkowska N, Mangeshkar S, Adal BH, Singh N. Racial and socioeconomic determinants of cardiovascular health: a comprehensive review. Cureus. 2024, 16:e59497. 10.7759\/cureus.59497","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/505138-gene-therapy-for-lipid-management-dawn-of-a-new-era","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:39:11Z","timestamp":1783903151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/505138-gene-therapy-for-lipid-management-dawn-of-a-new-era"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":59,"URL":"https:\/\/doi.org\/10.7759\/cureus.112496","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,11]]}}}